A detection kit for anti-cyclic citrullinated peptide antibodies and its application

By using protein A or protein G to capture protein and cyclic citrulline peptide latex microspheres in the anti-cyclic citrulline peptide antibody detection kit, the problems of inaccurate detection results and large errors in the prior art are solved, and the problem of inaccurate detection results and large errors are achieved. It has efficient and accurate antibody detection, suitable for clinical applications.

CN117388497BActive Publication Date: 2024-12-03SHENZHEN AMTECH BIOENGINEERING LTD INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311448258.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-02
Publication Date
2024-12-03
Estimated Expiration
2043-11-02

AI Technical Summary

Technical Problem

The existing anti-cyclic citrulline peptide antibody detection kits have problems such as cumbersome preparation methods, large batch differences, insufficient detection range, and insufficient specificity, resulting in inaccurate test results and large errors.

Method used

Provided is an anti-cyclic citrulline peptide antibody detection kit including reagent R1 and reagent R2. Reagent R1 contains protein A or protein G capture protein, binds to the Fc segment of the antibody, and reagent R2 contains cyclic citrulline peptide latex microspheres, Through specific combinations of buffers, surfactants, stabilizers and preservatives, efficient capture and binding of antibodies is achieved, improving detection sensitivity and specificity.

Benefits of technology

The preparation process of the kit is simplified, the batch difference is reduced, the accuracy and sensitivity of the test results are improved, and the high concentration of antibodies can be directly detected without dilution, which expands the detection range, and is suitable for a wide range of clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117388497B_ABST
    Figure CN117388497B_ABST
Patent Text Reader

Abstract

The present invention discloses a detection kit for anti-cyclic citrullinated peptide antibodies, comprising reagent R1 and reagent R2, wherein the reagent R1 comprises a capture protein for capturing anti-cyclic citrullinated peptide antibodies, a buffer with a pH of 5.5-8.5, an inorganic salt, a surfactant, a stabilizer, a coagulant and a preservative, wherein the capture protein is protein A, protein G or a combination thereof, wherein one of the protein A or protein G has 2-4 sites for binding to the Fc segment of the anti-cyclic citrullinated peptide antibodies, and the reagent R2 comprises cyclic citrullinated peptide latex microspheres, a buffer with a pH of 6.5-9.0, a surfactant, a stabilizer and a preservative. The reagent preparation method of the kit of the present invention is simple, the cost is low, the detection specificity is strong, the detection sensitivity is high, the result is accurate, no dilution is required, and the detection range is large.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biochemistry, and in particular to a detection kit for anti-cyclic citrullinated peptide antibodies and application thereof. Background Art

[0002] Rheumatoid arthritis (RA) is a common chronic autoimmune disease. About 1% of the world's population suffers from this disease. RA can cause pain, stiffness and swelling in the joints. Irreversible bone and joint damage may occur within 2 years of onset, and may cause a variety of complications, such as nervous system diseases, pericarditis, lymphadenitis, etc. Therefore, early diagnosis of RA and medication to alleviate the disease are very important for controlling the disease. The detection of anti-cyclic cirullinated peptide antibodies (anti-CCP antibodies), which was first reported abroad in 1998, has high sensitivity and specificity for RA and is a new serum marker for RA.

[0003] Anti-cyclic citrullinated peptide antibody (A-CCP) is an IgG-based antibody that exists in anti-filament aggregation-related antibodies in patients with rheumatoid arthritis (RA). It is secreted by B lymphocytes and has high specificity. It is a valuable auxiliary diagnostic indicator in the diagnosis of RA. The sensitivity of diagnosing RA through cyclic citrullinated peptide antibody detection is about 50%-75%, and the specificity is relatively high, usually above 90%.

[0004] There are various methodological anti-cyclic citrullinated peptide antibody detection kits on the market, such as enzyme-linked immunosorbent assay, chemiluminescence, immunoturbidimetry, etc. Although there are similar turbidimetric kits on the market, these kits have different problems. For example, the preparation method of some kits is cumbersome, or there are differences in each batch of reagents, and the consistency cannot be guaranteed, so the accuracy of the test results cannot be well guaranteed; some kits do not have a wide enough detection range, generally only 100-200 IU / mL, and high-value samples need to be diluted to test, which increases the number of detection steps and the possibility of errors. Some kits are not specific enough, and the test results will be false negative or false positive when there is interference. Summary of the invention

[0005] The present invention provides a detection kit for anti-cyclic citrullinated peptide antibodies, aiming to solve the above technical problems.

[0006] The invention provides a detection kit for anti-cyclic citrullinated peptide antibodies, comprising a reagent R1 and a reagent R2. The reagent R1 comprises a capture protein for capturing the anti-cyclic citrullinated peptide antibodies, a buffer with a pH value of 5.5-8.5, an inorganic salt, a surfactant, a stabilizer, a coagulant and a preservative. The capture protein is protein A, protein G or a combination thereof, and one of the protein A or protein G has 2-4 sites for binding to an Fc segment of the anti-cyclic citrullinated peptide antibodies. The reagent R2 comprises cyclic citrullinated peptide latex microspheres, a buffer with a pH value of 6.5-9.0, a surfactant, a stabilizer and a preservative.

[0007] Furthermore, the reagent R1 includes 0.5-5g / L of capture protein, 10-500mM of a buffer with a pH of 5.5-8.5, 2-50g / L of an inorganic salt, 0.05-10g / L of a surfactant, 0.5-50g / L of a stabilizer, 2-50g / L of a coagulant and 0.05-2g / L of a preservative, and the reagent R2 includes 0.5-5g / L of cyclic citrullinated peptide latex microspheres, 10-500mM of a buffer with a pH of 6.5-9.0, 0.05-10g / L of a surfactant, 1-100g / L of a stabilizer and 0.05-2g / L of a preservative.

[0008] Furthermore, the protein A is a natural protein or a recombinant protein, and the protein G is a recombinant protein with albumin and cell surface binding sites removed;

[0009] Furthermore, the protein A and the protein G are both recombinant fusion proteins.

[0010] Furthermore, the cyclic citrullinated peptide latex microspheres are conjugates of latex microspheres and cyclic citrullinated peptides covalently coupled.

[0011] Furthermore, the latex microspheres are polystyrene microspheres, and the particle size of the polystyrene microspheres is 50-400 nm, preferably 150-300 nm.

[0012] Furthermore, the latex microspheres have a charge of 10-150 μeq / g, preferably 20-50 μeq / g.

[0013] Furthermore, the surface of the latex microspheres is modified with groups.

[0014] Furthermore, the group is a carboxyl group, an amino group, an aldehyde group or a chloromethyl group.

[0015] Furthermore, the cyclic citrullinated peptide is a cyclic polypeptide containing citrulline, and the end of the cyclic polypeptide away from the citrulline is connected to a primary amino group.

[0016] Furthermore, the buffer is any one or more of phosphate, borate, carbonate, citrate, Tris-HCl and Good's buffer.

[0017] Furthermore, the preservative is any one or more of sodium azide, ProClin300, benzoates and gentamicin.

[0018] Furthermore, the surfactant is any one or more of polyoxyethylene sorbitan monolaurate, polyethylene glycol p-isooctylphenyl ether and alkylphenol polyoxyethylene ether.

[0019] Furthermore, the inorganic salt is any one or more of sodium sulfate, sodium chloride, potassium sulfate and ammonium chloride.

[0020] Furthermore, the coagulant is polyethylene glycol 6000-5000 or dextran 4000-50000.

[0021] Furthermore, the stabilizer is any one or more of sucrose, polysucrose, glucose, trehalose, bovine serum albumin and casein.

[0022] The present invention also provides a method for preparing the above-mentioned anti-cyclic citrullinated peptide antibody detection kit, characterized in that the method for preparing the cyclic citrullinated peptide latex microspheres comprises the following steps:

[0023] S1. Dilute the latex microspheres with buffer, then add the activator and shake at room temperature for 25-35 minutes;

[0024] S2. Wash the latex microspheres 2-3 times with a buffer solution, and then adjust the volume to a concentration of 0.9-1.1% (w / v);

[0025] S3. Add cyclic citrullinated peptide to the latex microspheres and mix immediately, shake on a shaker at room temperature for 1.8-2.2 hours, add glycine, and shake on a shaker at room temperature for 25-35 minutes;

[0026] S4. Remove the supernatant by centrifugation, wash the microspheres 2-3 times with 50 mM Tris-HCl buffer at pH 7.5, fix the volume to 1% (w / v), and store at 2-8°C.

[0027] Furthermore, the reagent R1 needs to be placed at 2-8°C for 12-48 hours after preparation.

[0028] The present invention also provides a method for detecting anti-cyclic citrullinated peptide antibodies, using the above-mentioned kit, comprising the following steps:

[0029] (1) Add the sample or calibrator to reagent R1, incubate at 37°C for 3 minutes, and then read the absorbance A1;

[0030] (2) Reagent R2 was added, and the absorbance A2 was read after incubation at 37°C for 5 minutes. The reaction degree ΔA was calculated, ΔA = A2 - A1;

[0031] (3) A calibration curve is drawn with the concentration of the calibrator as the horizontal axis and the reaction degree ΔA as the vertical axis. The reaction degree of the sample is substituted into the calibration curve to obtain the concentration of anti-cyclic citrullinated peptide in the sample.

[0032] The present invention also provides a use of the above-mentioned kit in detecting anti-cyclic citrullinated peptide antibodies in a sample, wherein the sample is blood.

[0033] Compared with the prior art, the present invention has the following beneficial effects:

[0034] 1. The reagent preparation method in the kit of the present invention is simple and low in cost. It only requires adding an appropriate amount of protein A or protein G to R1, without the need for a complex labeling process, thus reducing the batch difference in production, thereby ensuring the accuracy of the test results;

[0035] 2. Reagent R1 in the kit of the present invention captures all anti-cyclic citrullinated peptide IgG antibodies in the sample and is bound by the cyclic citrullinated peptide of reagent R2. Since the citrullinated epitope of the cyclic citrullinated peptide is far away from the binding end of the latex microsphere and there is no steric hindrance, the detection specificity is strong;

[0036] 3. The protein A or protein G of the kit of the present invention has 2-4 sites for binding to anti-cycloguanine peptide antibodies, which makes the particles bound by the antibody and cycloguanine peptide latex microspheres more obvious, improves the detection sensitivity, and can directly test high concentrations of anti-cycloguanine peptide antibodies in samples, with accurate results, no need for dilution, and improved detection range;

[0037] 4. The kit of the present invention is matched with a fully automatic biochemical analyzer or a specific protein analyzer, which can be used for rapid batch testing and is suitable for wide clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative labor.

[0039] Figure 1 is the calibration curve;

[0040] Figure 2 This is a method comparison chart;

[0041] Figure 3Schematic diagram of the reaction principle of the kit of the present invention. DETAILED DESCRIPTION

[0042] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments and drawings. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The present invention is specifically introduced below in conjunction with the specific embodiments.

[0043] An embodiment of the present invention provides a detection kit for anti-cyclic citrullinated peptide antibodies, comprising reagent R1 and reagent R2, wherein the reagent R1 comprises a capture protein for capturing the anti-cyclic citrullinated peptide antibodies, a buffer with a pH of 5.5-8.5, an inorganic salt, a surfactant, a stabilizer, a coagulant and a preservative, the capture protein is protein A, protein G or a combination thereof, and one of the protein A or protein G has 2-4 sites for binding to the Fc segment of the anti-cyclic citrullinated peptide antibody, and the reagent R2 comprises cyclic citrullinated peptide latex microspheres, a buffer with a pH of 6.5-9.0, a surfactant, a stabilizer and a preservative.

[0044] The detection principle of the kit is as follows: the excess protein A or protein G in reagent R1 can specifically adsorb the Fc segment of total IgG antibodies in human blood, including anti-cyclic citrullinated peptide antibody IgG, and can capture all anti-cyclic citrullinated peptide antibody IgG in the blood sample, and then encounter the cyclic citrullinated peptide latex microspheres in reagent R2 to form a large-particle network polymer of protein A / G-anti-cyclic citrullinated peptide antibody-cyclic citrullinated peptide latex microspheres, thereby forming turbidity, and the size of the turbidity is proportional to the content of anti-cyclic citrullinated peptide antibodies in the blood. When the sample does not contain or contains different amounts of anti-cyclic citrullinated peptide antibodies, different reactions occur accordingly, see Figure 3 .

[0045] Among them, buffers can adjust pH, inorganic salts can adjust ionic strength and reduce nonspecific reactions, surfactants can dissolve lipids in samples, stabilizers can maintain the stability of proteins in solution, coagulants can increase the binding rate of antigens and antibodies, and preservatives can prevent microbial contamination.

[0046] Specifically, the reagent R1 includes 0.5-5g / L capture protein, 10-500mM buffer with a pH of 5.5-8.5, 2-50g / L inorganic salt, 0.05-10g / L surfactant, 0.5-50g / L stabilizer, 2-50g / L coagulant and 0.05-2g / L preservative, and the reagent R2 includes 0.5-5g / L cyclic citrullinated peptide latex microspheres, 10-500mM buffer with a pH of 6.5-9.0, 0.05-10g / L surfactant, 1-100g / L stabilizer and 0.05-2g / L preservative.

[0047] Specifically, the protein A is a natural protein or a recombinant protein, and the protein G is a recombinant protein with albumin and cell surface binding sites removed;

[0048] Specifically, the protein A and the protein G are both recombinant fusion proteins.

[0049] Specifically, the cyclic citrullinated peptide latex microspheres are a conjugate of latex microspheres and cyclic citrullinated peptides covalently coupled.

[0050] Specifically, the latex microspheres are polystyrene microspheres, and the particle size of the polystyrene microspheres is 50-400 nm, preferably 150-300 nm.

[0051] Specifically, the latex microspheres have a charge of 10-150 μeq / g, preferably 20-50 μeq / g.

[0052] Specifically, the surface of the latex microspheres is modified with groups.

[0053] Specifically, the group is a carboxyl group, an amino group, an aldehyde group, a chloromethyl group, and the like.

[0054] Specifically, the cyclic citrullinated peptide is a cyclic polypeptide containing citrulline, and the end of the cyclic polypeptide away from the citrulline is connected to a primary amino group.

[0055] Specifically, the buffer is any one or more of phosphate, borate, carbonate, citrate, Tris-HCl and Good's buffer.

[0056] Specifically, the preservative is any one or more of sodium azide, ProClin300, benzoates and gentamicin.

[0057] Specifically, the surfactant is any one or more of polyoxyethylene sorbitan monolaurate, polyethylene glycol p-isooctylphenyl ether and alkylphenol polyoxyethylene ether.

[0058] Specifically, the inorganic salt is any one or more of sodium sulfate, sodium chloride, potassium sulfate and ammonium chloride.

[0059] Specifically, the coagulant is polyethylene glycol 6000-5000, dextran 4000-50000, etc.

[0060] Specifically, the stabilizer is any one or more of sucrose, polysucrose, glucose, trehalose, bovine serum albumin and casein.

[0061] The embodiment of the present invention also provides a method for preparing the above-mentioned anti-cyclic citrullinated peptide antibody detection kit, characterized in that the method for preparing the cyclic citrullinated peptide latex microspheres comprises the following steps:

[0062] S1. Dilute the latex microspheres with buffer, then add the activator and shake at room temperature for 25-35 minutes;

[0063] S2. Wash the latex microspheres 2-3 times with a buffer solution, and then adjust the volume to a concentration of 0.9-1.1% (w / v);

[0064] S3. Add cyclic citrullinated peptide to the latex microspheres and mix immediately, shake on a shaker at room temperature for 1.8-2.2 hours, add glycine, and shake on a shaker at room temperature for 25-35 minutes;

[0065] S4. Remove the supernatant by centrifugation, wash the microspheres 2-3 times with 50 mM Tris-HCl buffer at pH 7.5, fix the volume to 1% (w / v), and store at 2-8°C.

[0066] Specifically, the buffer used in step S1 and step S2 is 20 mM MES buffer with a pH of 6.1.

[0067] Specifically, the activating agent used in step S1 is EDC or NHS.

[0068] Specifically, the reagent R1 needs to be placed at 2-8° C. for 12-48 hours after preparation.

[0069] The present invention also provides a method for detecting anti-cyclic citrullinated peptide antibodies, using the above-mentioned kit, comprising the following steps:

[0070] (1) Add the sample or calibrator to reagent R1, incubate at 37°C for 3 minutes, and then read the absorbance A1;

[0071] (2) Reagent R2 was added, and the absorbance A2 was read after incubation at 37°C for 5 minutes. The reaction degree ΔA was calculated, ΔA = A2 - A1;

[0072] (3) A calibration curve is drawn with the concentration of the calibrator as the horizontal axis and the reaction degree ΔA as the vertical axis. The reaction degree of the sample is substituted into the calibration curve to obtain the concentration of anti-cyclic citrullinated peptide in the sample.

[0073] The embodiment of the present invention also provides a use of the above-mentioned kit in detecting anti-cyclic citrullinated peptide antibodies in a sample, wherein the sample is blood.

[0074] The following is explained in conjunction with specific embodiments:

[0075] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified, and the techniques not described in detail are all performed according to standard methods well known to those skilled in the art.

[0076] Example 1. Preparation of reagent R1 and reagent R2

[0077] Preparation of Reagent R1: The following components are required to prepare 1 liter of reagent R1:

[0078] Components Dosage Disodium hydrogen phosphate anhydrous 0.593g Sodium dihydrogen phosphate dihydrate 2.3g Protein A 3g Sodium chloride 9g Tween-20 2mL BSA 2g Sodium Azide 0.95mL Polyethylene glycol 6000 10g

[0079] First add 500 mL of purified water, then add the above components in order, adjust the pH to 7.5 with hydrochloric acid or sodium hydroxide at room temperature, make up to 1 liter, mix well, filter through a 0.45 μm filter membrane, and store at 2-8°C.

[0080] Preparation of Reagent R2: The following components are required to prepare 1 liter of reagent R2:

[0081] Components Dosage Tris(hydroxymethyl)aminomethane 12.11g Tween-20 0.5g sucrose 100g Sodium Azide 0.95mL Cyclic citrullinated peptide latex microspheres 2g

[0082] First, add 500 mL of purified water, then add the above components in order, adjust the pH to 8.0 with hydrochloric acid or sodium hydroxide at room temperature, then add cyclocitrullinated peptide latex microspheres and adjust the volume to 1 liter.

[0083] Wherein, the preparation method of cyclocitrullinated peptide latex microspheres is as follows:

[0084] CCP-NH2 was provided by Shenzhen Shangtai Bioengineering Co., Ltd. as a lyophilized powder, which was reconstituted with purified water to 1g / L for use. Take 10% (W / V) 200nm carboxyl polystyrene microspheres 1mL, add 10mL of 50mM MES pH6.0 buffer and mix well, then add 10mg EDC, mix at room temperature for 30 minutes, centrifuge and wash 3 times at 20000rpm, add 50mM MES pH6.0 buffer to make the volume 10mL, then add 1mg CCP-NH2, mix at room temperature for 2 hours, add glycine to 1% concentration, centrifuge at 20000rpm for 40 minutes, discard the supernatant, centrifuge and wash 3 times with 50mM Tris-HCl pH7.5 buffer, make the volume 1% with 50mM Tris-HCl pH7.5, and store at 2-8℃.

[0085] Example 2. Preparation of reagent R1 and reagent R2

[0086] Preparation of Reagent R1: The following components are required to prepare 1 liter of reagent R1:

[0087] Components Dosage Disodium hydrogen phosphate anhydrous 0.593g Sodium dihydrogen phosphate dihydrate 2.3g Protein G 2g Sodium chloride 9g Triton-100 1mL BSA 2g Sodium Azide 0.95mL Polyethylene glycol 6000 10g

[0088] First add 500 mL of purified water, then add the above components in order, adjust the pH to 7.5 with hydrochloric acid or sodium hydroxide at room temperature, make up to 1 liter, mix well, filter through a 0.45 μm filter membrane, and store at 2-8°C.

[0089] Preparation of Reagent R2: The following components are required to prepare 1 liter of reagent R2:

[0090] Components Dosage Tris(hydroxymethyl)aminomethane 12.11g Tween-20 1g sucrose 100g Sodium Azide 0.95mL Cyclic citrullinated peptide latex microspheres 1.6g

[0091] First, add 500 mL of purified water, then add the above components in order, adjust the pH to 8.0 with hydrochloric acid or sodium hydroxide at room temperature, then add cyclocitrullinated peptide latex microspheres (prepared by the same method as that of cyclocitrullinated peptide latex microspheres in Example 1), and adjust the volume to 1 liter.

[0092] Example 3. Preparation of reagent R1 and reagent R2

[0093] Preparation of Reagent R1: The following components are required to prepare 1 liter of reagent R1:

[0094] Components Dosage Tris(hydroxymethyl)aminomethane 12.11g Protein A 2g Protein G 1.5g Sodium chloride 12g Triton-100 1.5mL BSA 1g Sodium Azide 0.95mL Polyethylene glycol 6000 8g

[0095] First add 500 mL of purified water, then add the above components in order, adjust the pH to 7.5 with hydrochloric acid or sodium hydroxide at room temperature, make up to 1 liter, mix well, filter through a 0.45 micron filter membrane, and store at 2-8°C.

[0096] Preparation of Reagent R2: The following components are required to prepare 1 liter of reagent R2:

[0097] Components Dosage Tris(hydroxymethyl)aminomethane 12.11g Tween-20 1.2g sucrose 100g Sodium Azide 0.95mL Cyclic citrullinated peptide latex microspheres 1.4g

[0098] First, add 500 mL of purified water, then add the above components in order, adjust the pH to 8.0 with hydrochloric acid or sodium hydroxide at room temperature, then add cyclocitrullinated peptide latex microspheres (prepared by the same method as that of cyclocitrullinated peptide latex microspheres in Example 1), and adjust the volume to 1 liter.

[0099] Performance Testing

[0100] Test method: Take 5 μL of sample or standard of different concentrations (100, 200, 300, 400, 500, 600 IU / mL) and add it to 150 μL of reagent R1. Incubate at 37°C for 3 minutes and read the absorbance A1. Then add 50 μL of reagent R2 and incubate at 37°C for 5 minutes and read the absorbance A2. Draw a calibration curve with the concentration of the calibrator as the horizontal axis and the reaction degree ΔA (ΔA=A2-A1) as the vertical axis. See Figure 1 The reaction degree ΔA of the test sample is substituted into the calibration curve to obtain the concentration of anti-cyclic citrullinated peptide in the sample.

[0101] Testing instrument: Beckman AU680 biochemical analyzer;

[0102] Test wavelength: 570nm.

[0103] The results of the reagent evaluation are as follows:

[0104] Minimum detection limit

[0105] Use purified water as a blank sample, and repeat the test 20 times using the kit prepared in Example 1-3. The result below zero is reported as zero, and the mean value of the 20 results is calculated. AVE and standard deviation SD, X AVE +2SD is the detection limit.

[0106]

[0107]

[0108] As can be seen from the above table, the detection limits of the kits prepared in Examples 1-3 are all less than 2 U / mL, and the detection limits are better, indicating that the sensitivity is higher.

[0109] Repeatability

[0110] One negative serum and one positive serum were selected, and the test was repeated 10 times using the kit prepared in Examples 1-3, and the CV values ​​were calculated.

[0111]

[0112] As can be seen from the above table, the CV values ​​of the positive and negative samples tested by the kits prepared in Examples 1-3 were all relatively low, within 3%, indicating that the kit of the present invention has good repeatability.

[0113] Reportable Range

[0114] Reportable range lower limit test: The sample to be tested was diluted with mixed human serum to 5 concentrations close to the linear low value, and the test was repeated 10 times using the kit prepared in Examples 1-3. The minimum concentration with a CV value less than 10% was the reportable range lower limit.

[0115]

[0116]

[0117] As can be seen from the above table, the lower limit of the reportable range of the kit prepared in Example 1 is 2.178, the lower limit of the reportable range of the kit prepared in Example 2 is 2.029, and the lower limit of the reportable range of the kit prepared in Example 3 is 2.065.

[0118] Test for the upper limit of the reportable range: Select 3 samples with high concentration of A-CCP, add pure A-CCP if necessary, and calculate the theoretical value. Dilute the mixed serum by 2, 4, and 8 times respectively, so that it is close to the upper 1 / 3 area of ​​the linear range (the upper limit of the linear range is 600). Use the kit of the present invention to repeat the test 3 times for each sample, select the maximum dilution factor with a CV value less than 10%, and the high value of the linear range multiplied by the dilution factor is the upper limit of the reportable range.

[0119]

[0120] As can be seen from the above table, the upper limits of the reportable ranges of the kits prepared in Examples 1-3 are all 600×2=1200 IU / mL. Therefore, the reportable range of the kit of the present invention is 2.2-1200 IU / mL.

[0121] HOOK Effect

[0122] A series of A-CCP samples were selected, and pure A-CCP was added if necessary to make the theoretical value close to 25, 50, 100, 200, 400, 800, 1200, 1600, 2000, 2400, 2800, 3200, 3600 U / mL. The samples were tested using the kit prepared in Examples 1-3 and the absorbance value OD was recorded. A curve was drawn with A-CCP concentration as the abscissa and OD as the ordinate, and the A-CCP concentration corresponding to the peak of the curve was the highest concentration of the HOOK effect.

[0123] Example 1 Example 2 Example 3 Concentration (IU / mL) OD OD OD 25 638 559 699 50 1160 1021 1286 100 2036 1836 2168 200 3011 2591 2961 400 4151 3789 4218 800 5467 5061 5597 1200 6211 5892 6369 1600 6685 6369 6793 2000 6890 6657 6987 2400 6589 6520 6668 2800 5689 5891 5782 3200 4506 4786 4601 3600 3139 3369 3369

[0124] As can be seen from the above table, the A-CCP concentration measured using the kit prepared in Examples 1-3 has no HOOK effect within 2000 IU / mL.

[0125] Methodological comparison

[0126] 40 clinical patient samples with uniform A-CCP concentrations within 6-600 IU / mL were selected. A well-known manufacturer's A-CCP kit and the kit prepared in Example 1 were used for testing respectively, and each sample was tested twice to obtain the average value. The correlation coefficient and deviation were recorded.

[0127]

[0128]

[0129] Using the above results, see Figure 2 , the correlation coefficient R=0.9976, indicating that the kit of the present invention has a good correlation with the A-CCP kit of a well-known manufacturer.

[0130] The above results show that the anti-cyclic citrullinated peptide detection kit prepared by the present invention has good performance.

[0131] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A detection kit for anti-cyclic citrullinated peptide antibodies, It is characterized in that The invention comprises reagent R1 and reagent R2, wherein the reagent R1 comprises 0.5-5 g / L of a capture protein for capturing anti-cyclic citrullinated peptide antibodies, 10-500 mM of a buffer with a pH of 5.5-8.5, 2-50 g / L of an inorganic salt, 0.05-10 g / L of a surfactant, 0.5-50 g / L of a stabilizer, 2-50 g / L of a coagulant and 0.05-2 g / L of a preservative, wherein the capture protein is protein A, protein G or a combination thereof, wherein one of the protein A or protein G has 2-4 binding sites with the anti-cyclic citrullinated peptide antibodies. The Fc segment binding site of the acid peptide antibody, the reagent R2 includes 0.5-5g / L cyclic citrullinated peptide latex microspheres, 10-500mM buffer with a pH of 6.5-9.0, 0.05-10g / L surfactant, 1-100g / L stabilizer and 0.05-2g / L preservative; wherein the buffer is phosphate or Tris-HCl, the surfactant is Tween-20 or Triton-100, the stabilizer is bovine serum albumin or sucrose, and the coagulant is polyethylene glycol 6000; The protein A is a natural protein or a recombinant protein, and the protein G is a recombinant protein with albumin and cell surface binding sites removed; and / or, both the protein A and the protein G are recombinant fusion proteins.

2. The detection kit according to claim 1, It is characterized in that The cyclic citrullinated peptide latex microspheres are conjugates of latex microspheres and cyclic citrullinated peptides covalently coupled.

3. The detection kit according to claim 2, It is characterized in that The latex microspheres are polystyrene microspheres, and the particle size of the polystyrene microspheres is 50-400 nm; and / or, the latex microspheres have a charge of 10-150 μeq / g; And / or, the surface of the latex microspheres is modified with a group, and the group is a carboxyl group, an amino group, an aldehyde group or a chloromethyl group; And / or, the cyclic citrullinated peptide is a cyclic polypeptide containing citrulline, and the end of the cyclic polypeptide away from the citrulline is connected to a primary amino group.

4. The detection kit according to claim 1, It is characterized in that The preservative is any one or more of sodium azide, ProClin300, benzoates and gentamicin; And / or, the inorganic salt is any one or more of sodium sulfate, sodium chloride, potassium sulfate and ammonium chloride.

5. A method for preparing a detection kit for anti-cyclic citrullinated peptide antibodies according to any one of claims 1 to 4, It is characterized in that The preparation method of the cyclic citrullinated peptide latex microspheres comprises the following steps: S1. Dilute the latex microspheres with buffer, then add the activator and shake at room temperature for 25-35 minutes; S2. Wash the latex microspheres 2-3 times with a buffer solution, and then adjust the volume to a concentration of 0.9-1.1% (w / v); S3. Add cyclic citrullinated peptide to the latex microspheres and mix immediately, shake on a shaker at room temperature for 1.8-2.2 hours, add glycine, and shake on a shaker at room temperature for 25-35 minutes; S4. Remove the supernatant by centrifugation, wash the microspheres 2-3 times with 50 mM Tris-HCl buffer at pH 7.5, fix the volume to 1% (w / v), and store at 2-8°C.

6. The preparation method according to claim 5, It is characterized in that After the preparation, the reagent R1 needs to be placed at 2-8°C for 12-48 hours.

7. A method for detecting anti-cyclic citrullinated peptide antibodies for non-disease diagnosis purposes, It is characterized in that Using the kit as described in any one of claims 1 to 4, comprising the following steps: (1) Add the sample or calibrator to reagent R1, incubate at 37°C for 3 minutes, and then read the absorbance A1; (2) Reagent R2 was added, and the absorbance A2 was read after incubation at 37°C for 5 minutes. The reaction degree ΔA was calculated, ΔA = A2 - A1; (3) A calibration curve is drawn with the concentration of the calibrator as the horizontal axis and the reaction degree ΔA as the vertical axis. The reaction degree of the sample is substituted into the calibration curve to obtain the concentration of anti-cyclic citrullinated peptide in the sample.

Citation Information

Patent Citations

  • Kit for determining anti-cyclic citrullinated peptide (Anti-CCP) antibody

    CN102507918A

  • Anti-cyclic citrullinated peptide antibody detection kit

    CN107942067A